Salix Pharmaceuticals Revenue and Competitors

Bridgewater, USA

Location

$750M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Salix Pharmaceuticals's estimated annual revenue is currently $277.2M per year.(i)
  • Salix Pharmaceuticals received $0.8M in venture funding in January 2014.
  • Salix Pharmaceuticals's estimated revenue per employee is $321,600
  • Salix Pharmaceuticals's total funding is $750M.

Employee Data

  • Salix Pharmaceuticals has 862 Employees.(i)
  • Salix Pharmaceuticals grew their employee count by 14% last year.

Salix Pharmaceuticals's People

NameTitleEmail/Phone
1
CFOReveal Email/Phone
2
CEOReveal Email/Phone
3
VP Sales- GI and Primary Care DivisionsReveal Email/Phone
4
Director, Medical Affairs, Pain & Neurology Team LeadReveal Email/Phone
5
Director Digital StrategyReveal Email/Phone
6
Director, Commercial Learning & DevelopmentReveal Email/Phone
7
Senior Director MarketingReveal Email/Phone
8
Associate Director Medical AffairsReveal Email/Phone
9
Director, Commercial AnalyticsReveal Email/Phone
10
Executive Director Marketing, US Brand LeadReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$46.2M2305%N/AN/A
#2
$43.8M21821%N/AN/A
#3
$57.1M28426%N/AN/A
#4
$24.5M1223%N/AN/A
#5
$52.9M26313%N/AN/A
#6
$24.7M12313%N/AN/A
#7
$1.8M180%$114.3MN/A
#8
$7.2M36-20%N/AN/A
#9
$13.7M68-7%N/AN/A
#10
$7.6M39-13%$123.9MN/A
Add Company

What Is Salix Pharmaceuticals?

Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal (GI) diseases. We offer effective solutions and strive to be the first to discover what patients need next. We gain a deeper understanding of the GI conditions our products treat by connecting with the patients who use them and the healthcare professionals (HCPs) who prescribe them. Our therapeutic areas of expertise include management of conditions such as hepatic encephalopathy, irritable bowel syndrome with diarrhea, opioid-induced constipation, and ulcerative colitis. We employ dedicated and innovated team members who are driven to solve problems. We improve upon existing treatments, uncover new breakthroughs, and deliver comprehensive practice support to help HCPs provide best-in-class care. The landscape of healthcare will continue to change and new patients will continue to present with new needs. That's why there is no finish line for our innovation and no limits to our potential.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$750M

Total Funding

862

Number of Employees

$277.2M

Revenue (est)

14%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Salix Pharmaceuticals News

2022-04-20 - Hyaluronic Acid Market Size And Forecast | Allergan, Inc ...

Allergan, Inc.; Galderma and Salix Pharmaceuticals etc. The report provides a good overview of the key macroeconomic factors that have a...

2022-04-17 - Parkinson's Disease Therapeutics Market Size, Scope And ...

... Scope And Forecast | Leading Players – Salix Pharmaceuticals, ... Impax Laboratories, LLC, Teva Pharmaceutical Industries Ltd.

2022-04-06 - SALIX PHARMACEUTICALS WILL PRESENT SCIENTIFIC ...

BRIDGEWATER, N.J., April 7, 2022 /PRNewswire/ -- Salix Pharmaceuticals ("Salix"), the gastroenterology business of Bausch Health Companies...

2021-06-15 - Salix Will Share TRULANCE® (Plecanatide) Data At The 2021 AANP National Conference

BRIDGEWATER, N.J., June 15, 2021 /PRNewswire/ -- Salix Pharmaceuticals ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, announced today that data featuring TRULANCE® (plecanatide) will be share ...

2021-04-15 - New Report Reveals That More Than One-Third Of IBS Patients Surveyed State It Has Been More Challenging To Manage Their Symptoms During The COVID-19 Pandemic

Salix Pharmaceuticals Sponsored Report, Patient Perspectives: Living with IBS in a Pandemic Insights May Help Health Care Providers Have Productive Conversations with Their Patients About IBS Symptoms LAVAL, Quebec, April 15, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ...

Salix Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2002-03-12$49.8MPublic OfferingArticle
2003-11-11$30.6MPrivate PlacementArticle
2008-08-25$60.0MUndisclosedArticle
2012-03-19$690.0MUndisclosedArticle
2014-01-13$0.8MUndisclosedArticle